![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Merck has selected Carbon Health to participate in two double-blinded phase III International clinical trials to test the effectiveness of a new COVID-19 antiviral treatment pill, molnupiravir for both treatment and prophylaxis indications.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 30, 2021